Management of acute and recurrent hypoglycaemia

Rory J. McCrimmon (Lead / Corresponding author)

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)


Hypoglycaemia is a frequent adverse effect of insulin and sulfonylurea therapy for diabetes. Hypoglycaemia develops as a consequence of the limitations of current therapies and their delivery systems and because most individuals with insulin and/or sulfonylurea-treated diabetes develop widespread defects in their counterregulatory defence responses against low glucose. The initial focus of this chapter is discussion of factors or co-morbidities that may increase hypoglycaemia risk. Subsequently, the approaches used to identify the pattern of hypoglycaemia in any one individual are examined, including use of the new continuous glucose monitoring systems. Guidelines for the management of both acute and recurrent hypoglycaemia are then assessed and the evidence is reviewed in favour of any given approach. Structured educational programmes, insulin analogues, insulin pump therapy, continuous glucose monitoring, the artificial pancreas as well as more novel approaches are reviewed. At present, there is no clear support for any one approach to management and treatments have to be tailored to the individual.
Original languageEnglish
Title of host publicationHypoglycaemia in clinical diabetes
EditorsBrian M. Frier, Simon R. Heller, Rory J. McCrimmon
Place of PublicationOxford, UK
Number of pages19
ISBN (Print)9780470672006, 9781118695432
Publication statusPublished - 8 Jan 2014


Dive into the research topics of 'Management of acute and recurrent hypoglycaemia'. Together they form a unique fingerprint.

Cite this